February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month. Here's why they like AbbVie (ABBV -1.23%), Amgen (AMGN -1.42%), and Gilead Sciences (GILD -2.04%).Resurging dividend royaltyKeith Speights (AbbVie): AbbVie has been a longtime favorite for income investors. The big drugmaker's 52 consecutive years of dividend increases (including when it was p ...

Group 1: AbbVie - AbbVie has faced challenges, including the loss of patent exclusivity for its top-selling drug, Humira, leading to a significant drop in revenue and share price in early 2023 [2] - Despite setbacks, AbbVie's revenue for 2024 increased by 3.7% to $56.3 billion, and adjusted earnings per share decreased by 9% year over year to $10.12, partly due to acquisition-related expenses [4] - AbbVie is recognized as a Dividend King with 52 consecutive years of dividend increases and offers a forward yield of about 3.7%, making it attractive for income investors [5] Group 2: Gilead Sciences - Gilead Sciences' shares have increased by almost 29% over the trailing-12-month period, with a forward P/E of 12.9 indicating it may be undervalued [6] - The company's revenue for the first nine months of 2024 rose by 6% year over year to $21.2 billion, while adjusted EPS was $2.72, down almost 46% compared to the previous year due to acquisition-related charges [6][7] - Gilead has made significant progress in its pipeline, focusing on various therapeutic areas, including HIV and oncology, and has increased its dividend by about 79% over the past 10 years, with a forward yield of approximately 3.1% [8][9]

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.Inflation is like a hidden force that stops for no one. One of the best ways to stay ahead of inflation is to buy income-generating assets that are tied to t ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1NORTH CHICAGO, ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability to automate complex workflows and enhance productivity is seen as a game-changer for the next generation of innovation.Perhaps the most promising AI application is its potential to revolutionize medicine by accelerating the drug discovery process to deliver more effective therapies. Several biotechnology companies are embracing these cutting-edge capabilities to unlock new growth oppo ...

Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY. IRVINE, Calif., Feb. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced a nationwide open casting call in search of the next Faces of Natrelle®, encouraging women who have experienced breast rec ...

AbbVie (ABBV) announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% on an operational basis, mainly driven by robust sales of its immunology medicines, Skyrizi and Rinvoq. While sales of Skyrizi rose 57.9% on an operational basis, Rinvoq sales were up 47.1%. AbbVie’s other key drugs, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elah ...

POLAND - 2024/11/17: In this photo illustration, the AbbVie company logo is seen displayed on a ... [+] smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectivel ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .If you ask someone who owns a construction company in the Sunbelt, odds are he or she is upbeat, supported by economic re-shoring and a lot ofAnalyst’s Disclosure: I/we have a beneficial long position in the shares of NSC, UNP, CP, ABBV either through stock ownership, options, o ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.AbbVie Inc. (NYSE: ABBV ) stock has surged by over 7% in trading so far today, as the company released its Q4 earnings and full-year 2024 earnings, and provided guidance fo ...